COVID-19-related mortality in the onco-hematological setting is higher than in general
population, and patients with multiple myeloma (MM) have been reported to be particularly …

“Coronavirus Disease 2019”(COVID-19) due to SARS-CoV-2 infection is characterized by a
poorer outcome in patients with hematologic malignancies [1, 2]. Specifically, several papers …

Lymphopenia (particularly low CD19+ B-lymphocyte count) and current treatment with either
anti-CD38 or anti-BCMA monoclonal antibodies (MoAbs) have been reported to significantly …

Patients with multiple myeloma frequently present with substantial immune impairment and
an increased risk for infections and infection-related mortality. The risk for infection with …

Patients with multiple myeloma (MM) appear particularly vulnerable to SARS-CoV-2
infection due to compromised humoral and cellular immunity and to anti-tumor treatments …

Patients affected by multiple myeloma (MM) have an increased risk of severe acute
respiratory syndrome coronavirus type 2 (SARS‐CoV‐2) infection and subsequent …

Patients with multiple myeloma (MM) are at increased risk for severe clinical symptoms and
mortality due to SARS-CoV-2 infection. To protect against these complications, the …

Despite the efficacy of COVID-19 vaccines in healthy individuals, multiple myeloma (MM)
patients are immunocompromised and mount suboptimal humoral and cellular responses …

In the post-pandemic COVID-19 period, human activities have returned to normal and
COVID-19 cases are usually mild. However, patients with multiple myeloma (MM) present an …

We conducted a prospective, three-center, observational study in Japan to evaluate the
prevalence of seropositivity and clinically protective titer after coronavirus disease 2019 …